Exploiting MEK Inhibitor-Mediated Activation of ERα for Therapeutic Intervention in ER-Positive Ovarian Carcinoma

While the clinical benefit of MEK inhibitor (MEKi)-based therapy is well established in Raf mutant malignancies, its utility as a suppressor of hyperactive MAPK signaling in the absence of mutated Raf or Ras, is an area of ongoing research. MAPK activation is associated with loss of ERα expression a...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Main Authors: Hou, June Y., Rodriguez-Gabin, Alicia, Samaweera, Leleesha, Hazan, Rachel, Goldberg, Gary L., Horwitz, Susan Band, McDaid, Hayley M.
Formato: Artigo
Idioma:Inglês
Publicado em: Public Library of Science 2013
Assuntos:
Research Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC3563537/
https://ncbi.nlm.nih.gov/pubmed/23390495
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1371/journal.pone.0054103
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados